Abstract
Background: Pulmonary sarcomatoid carcinoma (PSC) as a rare subtype of nonsmall cell lung cancer (NSCLC) is resistant to conventional chemotherapy and radiotherapy with poor prognosis. Nivolumab is a monoclonal antibody against PD-1 and might be a valuable therapy option for PSC, but limited case reports have shown good response. Case presentation: A 61-year-old man with PSC characterized with KRAS-G12C mutation and TP53 mutation received treatment of nivolumab synchronously combined with hydrogen inhalation. Clinical symptoms gradually relieved, and evaluation on imaging revealed a response after 1 year. Conclusion: This case suggests that immunotherapy combined with hydrogen inhalation may potentially be a promising strategy to treat PSC patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
